AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Vaccine Demonstrates 18% Response In Non-Small-Cell Disease.(Brief Article)
2001 JUN 20 - (NewsRx.com & NewsRx.net) --
Cell Genesys, Inc. (CEGE) reported data on its GVAX(R) lung cancer vaccine that demonstrate anti-tumor activity has been observed in every cancer that the GVAX vaccine has been tested in to date.
The company is currently preparing for Phase III trials. Interim clinical data from Cell Genesys' multicenter Phase I/II GVAX lung cancer vaccine trial demonstrated objective evidence of anti-tumor activity including a major response rate of 18% in patients with advanced non-small-cell lung cancer who had failed chemotherapy and/or radiation therapy.
The interim clinical trial data, presented at the June 2001 American Society of Gene Therapy (ASGT) in Seattle, Washington, included results on 30 currently evaluable patients with advanced or early-stage lung cancer. Of 22 patients with advanced lung cancer, three patients, two of whom had failed chemotherapy and one who failed radiation therapy, showed a complete disappearance of metastatic tumors following treatment with GVAX lung cancer vaccine. One other patient who failed radiation and chemotherapy had partial (greater than 50%) reduction in tumor size.
In addition to these major responses, four patients currently have ...
- Cell Genesys Reacquires Full Commercial Rights to GVAX(R) Lung Cancer Vaccines.
- Press release article from: PR Newswire October 18, 2002 700+ words
...International Lung Cancer Congress, Cell Genesys presented the...on GVAX(R) lung cancer vaccines. Under...modified agreement, Cell Genesys would pay JT...for GVAX(R) lung cancer vaccine products. Cell Genesys' GVAX(R...
- Cell Genesys Advances GVAX(R) Lung Cancer Vaccine To Multicenter Phase I/II...
- Press release article from: PR Newswire April 7, 2000 700+ words
...cancers, including lung cancer. Cell Genesys is developing GVAX...in December 1998. Cell Genesys' GVAX(R) lung cancer vaccine is a patient...how to participate in Cell Genesys' GVAX(R) lung cancer vaccine trials can...
- Cell Genesys Reports Encouraging Update From Multicenter Clinical Trial Of...
- Press release article from: PR Newswire December 16, 2002 700+ words
...non small-cell lung cancer. In the Cell Genesys-sponsored study...receive GVAX(R) lung cancer vaccine with or without...non small-cell lung cancer is targeted to begin...In related news, Cell Genesys announced that it...
- Cell Genesys Reports Further Encouraging Results From Initial Phase I/II Trial...
- Press release article from: PR Newswire September 12, 2000 700+ words
...initial trial, Cell Genesys initiated...GVAX(R) lung cancer vaccine in...addition, Cell Genesys plans to develop...product for lung cancer since other...cancer and lung cancer are being developed by Cell Genesys through a...
- Cell Genesys Announces Initiation of Phase 2 Trial of GVAX(R) Lung Cancer...
- Press release article from: PR Newswire June 28, 2004 700+ words
...chief operating officer of Cell Genesys. "Bronchoalveolar lung cancer is generally less responsive...specific GVAX(R) lung cancer vaccines for clinical trials. Cell Genesys is now manufacturing GVAX(R) lung cancer vaccines in its 35,000...
- Cell Genesys reacquires full commercial rights to Gvax lung cancer vaccines.
- News wire article from: Asia Africa Intelligence Wire October 18, 2002 700+ words
...Press Release) Cell Genesys Inc has reacquired...rights to Gvax lung cancer vaccines following...primarily on Gvax lung cancer vaccines. Under...modified agreement, Cell Genesys would pay Japan...royalty on Gvax lung cancer vaccine sales...
- Cell Genesys Confirms Publication of Scientific Paper on GVAX(R) Lung Cancer...
- Press release article from: PR Newswire February 20, 2004 700+ words
...clinical trial of Cell Genesys' GVAX(R) lung cancer vaccine trial...of Cancer. Cell Genesys is currently...GVAX(R) lung cancer vaccine to...small-cell lung cancer and is expected...quarter of 2004. Cell Genesys is focused...
- Cell Genesys Comments on CBS Segment Highlighting Preliminary Clinical Result...
- Press release article from: PR Newswire November 16, 2000 700+ words
...result from Cell Genesys' ongoing Phase...GVAX(R) lung cancer vaccine clinical...is treated. Cell Genesys plans to develop...product for lung cancer since other...participate in Cell Genesys' GVAX(R) lung cancer vaccine trials...
- Cell Genesys to Start Lung Cancer Vaccine Trial in Memphis, Tenn.
- Newspaper article from: The Commercial Appeal (Memphis, Tennessee) (via Knight-Ridder/Tribune Business News) March 6, 2002 700+ words
...That's when Cell Genesys plans to start...for its GVAX lung cancer vaccine from...Stephen Sherwin, Cell Genesys chairman and...26 latestage lung cancer patients for...wonderful benefit." Cell Genesys chose to operate...
- Cell Genesys Secures Memphis Facility for Manufacturing of Patient-Specific...
- Press release article from: PR Newswire February 12, 2002 700+ words
...sets the stage for Cell Genesys' product development...for GVAX(R) lung cancer vaccines which...surgical biopsy. In Cell Genesys' initial Phase II GVAX(R) lung cancer vaccine trial...received GVAX(R) lung cancer vaccine following...of 12 months. ...
Source: HighBeam Research, Vaccine Demonstrates 18% Response In Non-Small-Cell Disease.(Brief...